Jason Hendrix, MD
Ophthalmology · St George, UTNPI 1831117167
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 64 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Alcon at 53.0% of the total. Reporting peaked in 2021 at $397 and has fallen 50.2% since, to $198 in 2025.
Across 64 payments — averaging $24.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$825
- AbbVie$231
- Aerie Pharmaceuticals, Inc.$118
- Novartis$55
- Glaukos Corporation$51
- Mallinckrodt Hospital Products Inc.$44
- plus $231 from 10 others
Across 123 payments — averaging $4723.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$261K
- AbbVie$219K
- Novartis$101K
What the payments were for
- Food & beverage$1,556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 27 | $825 |
| AbbVie(2 entities) | 11 | $231 |
| Aerie Pharmaceuticals, Inc. | 6 | $118 |
| Novartis | 3 | $55 |
| Glaukos Corporation | 1 | $51 |
| Mallinckrodt Hospital Products Inc. | 2 | $44 |
| Sun Pharmaceutical Industries Inc. | 2 | $44 |
| Tarsus Pharmaceuticals, Inc. | 2 | $36 |
| Biotissue Holdings Inc. | 2 | $35 |
| Eyepoint US, Inc. | 2 | $31 |
| Dompe US, Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
| Sight Sciences, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $12 |
| Rxsight Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$224
- AcrySof IQ PanOptix$129
How this compares
$1,556 in reported general payments places this provider in the 60th percentile of 191 ophthalmology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 24 | $21,909 |
| LumiganBimatoprost | 27 | $16,571 |
| Bromfenac Sodium | 102 | $8,843 |
| Prednisolone Acetate | 79 | $2,895 |
| Travoprost | 20 | $1,399 |
| Latanoprost | 187 | $1,277 |
| Ketorolac Tromethamine | 32 | $678 |
| Timolol Maleate | 84 | $481 |
| Brimonidine Tartrate | 42 | $433 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 33 | $344 |
| Bimatoprost | 16 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $231 | $38,48051 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 191 ophthalmology providers in Utah.
Other ophthalmology in St George
- Sharon RichensSt George$26K
- David SladeSt George$8K
- Shawno MaySt George$4K
- William WagnerSt George$3K
- Iqbal AhmedSalt Lake City$895K
- Robert CionniSalt Lake City$161K
- Ron LordSt. George$61K
- Zachary ZavodniSalt Lake City$51K
- Majid MoshirfarSalt Lake City$44K
- Marc Steffen Schmitz-ValckenbergSalt Lake City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.